Abstract | PURPOSE: PATIENTS AND METHODS: Sixty-two eligible patients with a histologic diagnosis of NHL were enrolled, 35 of who had intermediate or high-grade histologies and 27 of who had low-grade lymphomas. Patients with intermediate or high-grade lymphomas had received only 1 prior chemotherapy regimen, while patients with low-grade histologies had received 1 or 2 prior chemotherapy regimens. Menogaril was administered at 160 mg/m2 intravenously over 1 hour, once every 28 days. RESULTS: Among the 35 patients with intermediate or high-grade lymphomas who were evaluable for response, 6 of 35 patients achieved a partial response (PR) for a response rate of 17% (95% confidence interval: 7%-34%). Median survival in this group of patients was 13 months. For those patients with low-grade lymphoma, 5 of 26 patients achieved a PR for a response rate of 19% (95% confidence interval: 6%-38%). No complete responses were observed in either patient group. The incidence of serious (grade 3 or 4) toxicity for those with intermediate/high-grade and low-grade lymphomas was 43% and 44%, respectively. Most of these toxic effects consisted of reversible myelosuppression. Menogaril was discontinued in 2 patients due to prolonged neutropenia. Cardiotoxicity was observed in 4 patients, requiring discontinuation of the drug in 1 patient. No treatment-related deaths occurred and the overall toxicity was felt to be acceptable. CONCLUSION: The observed antitumor activity of single agent menogaril against both intermediate/high-grade and low-grade lymphomas was modest. Further exploration of this agent in patients with non-Hodgkin's lymphomas does not seem warranted.
|
Authors | D F Moore Jr, T D Brown, M LeBlanc, S Dahlberg, T P Miller, S McClure, R I Fisher |
Journal | Investigational new drugs
(Invest New Drugs)
Vol. 17
Issue 2
Pg. 169-72
( 1999)
ISSN: 0167-6997 [Print] United States |
PMID | 10638487
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
- Antibiotics, Antineoplastic
- Menogaril
|
Topics |
- Aged
- Antibiotics, Antineoplastic
(adverse effects, therapeutic use)
- Female
- Humans
- Lymphoma, Non-Hodgkin
(drug therapy)
- Male
- Menogaril
(adverse effects, therapeutic use)
- Middle Aged
- Neoplasm Staging
- Patient Dropouts
- Survival Rate
- Treatment Outcome
|